Who are tbo-filgrastim's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rolvedon, Neulasta, Neupogen, FILGRASTIM, Leukine, FYLNETRA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tbo-filgrastim.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

tbo-filgrastim — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

tbo-filgrastim (tbo-filgrastim) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Leukocyte Growth Factor [EPC]. Area: Oncology.

discontinued Leukocyte Growth Factor [EPC] Oncology Small molecule Live · refreshed every 30 min

Target snapshot

tbo-filgrastim (tbo-filgrastim) — Teva Branded Pharmaceutical Products R&D, Inc.. 12.1 Mechanism of Action Tbo-filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates proliferation of neutrophils. G-CSF is known to stimulate differentiation commitment and some end-cell functional activation, which increases neutrophil counts and activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
tbo-filgrastim TARGET	tbo-filgrastim	Teva Branded Pharmaceutical Products R&D, Inc.	discontinued	Leukocyte Growth Factor [EPC]
Rolvedon	EFLAPEGRASTIM	Spectrum Pharms	marketed	Leukocyte Growth Factor [EPC]	Granulocyte colony-stimulating factor receptor	2022-01-01
Neulasta	PEGFILGRASTIM	Amgen	marketed	Leukocyte Growth Factor [EPC]	Granulocyte colony-stimulating factor receptor	2002-01-01
Neupogen	Filgrastim-Aafi	Amgen	marketed	Colony-stimulating factor (CSF); leukocyte growth factor	G-CSF receptor (granulocyte colony-stimulating factor receptor)	1991-01-01
FILGRASTIM	FILGRASTIM		marketed	Leukocyte Growth Factor [EPC]	Specific cell surface receptors on hematopoietic cells	1991-01-01
Leukine	SARGRAMOSTIM	Berlex Labs	marketed	Leukocyte Growth Factor [EPC]	Granulocyte macrophage colony-stimulating factor receptor	1991-01-01
FYLNETRA	PEGFILGRASTIM-PBBK	KASHIV BIOSCIENCES LLC	marketed	Leukocyte Growth Factor [EPC]	specific cell surface receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tbo-filgrastim — Competitive Intelligence Brief. https://druglandscape.com/ci/tbo-filgrastim. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing